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View and review
The fragile x-associated tremor 
and ataxia syndrome (fxTas)
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AbstrAct
FXTAS (Fragile X-associated tremor and ataxia syndrome) is a late- onset neurodegenerative 
disorder affecting mainly men, over 50 years of age, who are carriers of the FMR1 gene 
premutation. The full mutation of this gene causes the fragile X syndrome (FXS), the most 
common cause of inherited mental retardation. Individuals affected by FXTAS generally 
present intention tremor and gait ataxia that might be associated to specific radiological 
and/or neuropathological signs. Other features commonly observed are parkinsonism, 
cognitive decline, peripheral neuropathy and autonomic dysfunction. Nearly a decade after 
its clinical characterization, FXTAS is poorly recognized in Brazil. Here we present a review 
of the current knowledge on the clinical, genetic and diagnostic aspects of the disease.
Key words: FXTAS, fragile X-associated tremor/ataxia syndrome, fragile X syndrome, 
movement disorders, essential tremor, gait ataxia, CGG repeats, FMR1 gene.
A síndrome de tremor e ataxia associada ao X frágil (FXtAs)
resumo
A FXTAS (síndrome de tremor e ataxia associada ao X frágil) é uma doença neurodegenerativa 
de início tardio que afeta principalmente homens acima dos 50 anos de idade, portadores 
de pré-mutação do gene FMR1. A mutação completa desse gene é responsável pela 
síndrome do cromossomo X frágil (SXF), a causa mais comum de deficiência mental 
herdada. Indivíduos afetados pela FXTAS geralmente apresentam tremor de intenção e 
ataxia de marcha que podem estar associados a sinais radiológicos ou neuropatológicos 
específicos. Outras características comumente observadas são parkinsonismo, declínio 
cognitivo, neuropatia periférica e disfunções autonômicas. Quase uma década após sua 
caracterização clínica, a FXTAS é mal conhecida por médicos no Brasil. Esta revisão apresenta 
o conhecimento atual sobre os aspectos clínicos, genéticos e diagnósticos da síndrome. 
Palavras-chave: FXTAS, tremor e ataxia associados ao X frágil, síndrome do X frágil, 
distúrbios do movimento, tremor essencial, ataxia de marcha, repetições CGG, gene FMR1.
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By the end of the 1990s, the occurrence 
of an unknown neurological disease affect-
ing the elderly was brought to the atten-
tion of the Hagermans, at the University 
of Colorado, Denver, USA. For some years 
already, their main research interest had 
been the Fragile X Syndrome (FXS, MIM 
300624), the most frequent form of inher-
ited mental retardation, caused by the mu-
tation of the FMR1 gene (Fragile X Men-
tal Retardation 1 gene, MIM 309550), on 
the X chromosome. The recurrent reports 
on fallings and difficulties to perform dai-
ly activities in consequence of tremor ex-
perienced by maternal grandparents of the 
mentally retarded boys prompted them to 
investigate these complains in detail. In 
2000, during the 7th International Fragile X 
Conference, Los Angeles, California, USA, 
attended by researchers, physicians and 
FXS relatives, a neurological evaluation of 
grandparents in FXS families was present-
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ed, and approximately one third of FXS relatives in the au-
dience declared the presence of the neurological signs in 
elderly members of their families. This gave further sup-
port to the idea that a neurological syndrome was associ-
ated to the premutation of the FMR1 gene. This syndrome 
was characterized and named FXTAS (Fragile X associ-
ated - tremor and ataxia syndrome; MIM 300623)1-3.
The FMR1 gene contains a 5’ untranslated CGG repeat 
- (CGG)n - that is polymorphic in the general population, 
varying in length from 6 to about 55 triplets [(CGG)6 to 
(CGG)~55]. Premutations are characterized by expanded 
(CGG)n between 55 to 200 triplets; these alleles are func-
tional, producing both messenger RNA (FMR1 mRNA) 
and protein (FMRP, fragile X mental retardation protein). 
When the (CGG)n is expanded to more than 200 triplets 
- a full mutation - the gene becomes non-functional, as 
the consequence of abnormal methylation of the adjacent 
CpG island and the repeat itself. The absence of the pro-
tein, the FMRP, is responsible for the fragile X syndrome, 
the most common cause of inherited mental retardation 
(review in Jacquemont and coleagues4). 
The clinical picture of FXS (mental retardation, mac-
roorchidism, facial abnormalities, joint laxity, hyperactiv-
ity and autistic features) is completely distinct from the 
FXTAS phenotype. In FXTAS, intention tremor and gait 
ataxia are the major clinical symptoms; parkinsonism, 
cognitive decline, peripheral neuropathy and autonom-
ic dysfunctions might be associated. Radiological and 
neuropathological features also contribute to the estab-
lishment of the FXTAS diagnostic. The relatively recent 
nine-year description of the FXTAS contrasts with about 
three decades of clinical characterization of the FXS and 
the identification of FMR1 as the gene responsible for 
the disease 19 years ago2. This late recognition of FXTAS 
might be the consequence of the occurrence of two com-
pletely distinct clinical entities associated with the same 
gene: a neurodevelopmental disease, the FXS, present 
since childhood without any significant progression dur-
ing adulthood, and a late-onset neurodegenerative disor-
der manifested after the fifth decade of life, the FXTAS. In 
addition, it was believed that the functional premutation 
could not cause neurological problems, and the move-
ment disorders observed in a number of elderly FXS rel-
atives were ascribed to the aging process2,5,6.
FXTAS is not the only condition associated to the pre-
mutation of the FMR1 gene. Premutated women tend to 
present primary ovarian insufficiency (FXPOI, fragile X-
associated primary ovarian insufficiency), and about 20% 
of them have premature menopause (POF, cessation of 
menses before 40 years of age)7,8.
fxTas - Case description
Here we summarize the clinical and radiological fea-
tures of one male patient affected by FXTAS who was 
identified in a Brazilian FXS/FXTAS/POF family reported 
by Capelli and coleagues9. This patient, a retired watch-
man, started with gait difficulties and frequent fallings 
due to the sensation of weakness in the lower limbs, at the 
age of 59 years. In the following years, intention tremor 
appeared in the upper limbs, impairing execution of dai-
ly tasks, as eating and writing. At 72 years of age, a cane 
was necessary to support locomotion. Neurological ex-
amination, at 74 years of age, revealed a definite low score 
in the Mini-Mental State Examination (18 points), despite 
his 8 years of schooling. The patient presented global cer-
ebellar syndrome evidenced by tendon dance, dysarthria, 
gait ataxia, dyssynergy, dysdiadochokinesia and dysme-
tria, in addition to postural and kinetic tremor in the up-
per limbs, scoring 45/100 in ICARS. Mild parkinsonism 
was noticed by rest tremor in the right hand. A peripheral 
motor syndrome was detected, with reduction of strength 
in the lower limbs and absence of reflexes. Non-inhibited 
bladder was observed. 
Magnetic resonance imaging (MRI) revealed in axi-
al FLAIR images cortical and subcortical atrophy, sym-
metric lesions in the periventricular white matter and hy-
persignal in the middle cerebellar peduncle (Figure) .This 
patient passed away at the age of 77 years in an accident. 
Neuropathological analysis or autopsy of the brain was 
not performed. He was a carrier of a FMR1 premutation 
with (CGG)109.
fxTas: Clinical, radiological and 
neuropathological aspects
Following the initial description of FXTAS1, sever-
al studies on its symptoms and signs allowed establish-
ing a clinical, radiological and pathological picture of the 
syndrome. 
– Progressive intention tremor mainly observed dur-
ing intentional movements aiming at performing daily 
tasks (eating, writing, and grabbing objects) or during 
maintenance of a position against gravity (postural trem-
or). Tremor causes moderate-to-severe incapacity, gen-
erally affecting the upper limbs, first the dominant hand, 
and then the other hand5,10.
– Gait Ataxia: FXTAS patients initially exhibit wide-
based gait, frequent fallings and incapacity of tandem 
gait. Progressively, locomotor supports (cane, walker) 
become necessary and, at the final stages of the disease, 
individuals are confined to wheelchairs or, eventually, 
bedridden10,11.
– Cognitive decline is generally evidenced by de-
crease of attention control, working memory, execu-
tive functioning, and learning in contrast to the relative 
preservation of speech, visual and spatial abilities. Mood 
and behavioral abnormalities such as depression, mood 
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switches, disinhibition, irritability, inappropriate or reclu-
sive behavior and anxiety are usually present. This pattern 
is consistent with the frontal-subcortical type of demen-
tia. Generally the FXTAS leads to complete loss of auton-
omy due to dementia5,10-15.
– Parkinsonism is characterized by slowness of 
movements, rigidity, rest tremor and reduction of facial 
expression10,16.
– Peripheral neuropathy affects the lower limbs and 
is characterized by decrease or loss of deep tendon reflex-
es, reduction of touch and vibration sensations, tingling, 
lower extremity pain, abnormalities in proprioceptive re-
sponse, and muscular weakness in the proximal portion 
of the lower limbs2,10,17.
– Autonomic dysfunctions: bowel incontinency, blad-
der incontinency and impotence are frequently observed5.
The first symptom of the disease varies between inten-
tion tremor1,11,18,19 or gait ataxia2,5,10, generally beginning 
between 50 and 70 years of age (mean of 60 years). Not 
always these two symptoms appear concomitantly but, 
independently of the order of appearance, in up to two 
years they are generally present, as in the case reported 
above. Beginning of falls occurs around six years after the 
appearance of motor problems, and necessity of locomo-
tion support is present between 5 to 15 years. Then, par-
kinsonism, peripheral neuropathy, cognitive decline and 
autonomic dysfunctions might appear. The diagnosis of 
FXTAS is performed approximately 10 years after the ini-
tial symptoms. Life expectancy is variable, between 5 to 
25 years after diagnosis, with a mean of about 21 years. 
End-stages of FXTAS include laryngeal muscle weakness 
and death is commonly caused by dysphagia10,17,19,20.
In addition to the clinical features, radiological and 
neuropathological signs also contribute to establish the 
correct diagnosis of FXTAS. Magnetic resonance imaging 
(MRI) examination revealed an abnormal brain pattern, 
which allowed classifying the syndrome as a white matter 
disease, affecting the periventricular and the subcortical 
regions of the brain. The principal radiological sign is the 
hyperintensity of the middle cerebellar peduncle (MCP 
sign) seen in T2 and FLAIR acquisitions5,21, which is pres-
ent in 60% of the FXTAS patients10. Generalized brain at-
rophy, with decrease in volume of cerebrum (mainly the 
parietal and frontal regions), mesencephalon, pons and 
cerebellum is observed, always disproportional for age21,22.
The abnormalities observed in MRI agreed with the 
neuroanatomical analyses of 11 brains of individuals who 
died with FXTAS, which exhibited degenerated regions 
and demyelination in white matter of cerebrum and cere-
bellum, mild to moderate cortical atrophy, increased size 
of the brain ventricles and spongiform intercellular ede-
ma in the middle cerebellar peduncle, corresponding to 
the MCP sign21,23.
Neuropathological analyses also contribute to FXTAS 
diagnosis. Postmortem examination revealed the presence 
of eosinophilic intranuclear inclusions in neurons and as-
trocytes throughout cortex, basal ganglia, thalamus, sub-
stantia nigra, dentate nucleus and brainstem, with the 
highest number in hippocampus. Inclusions were also 
observed in neurons of the cranial nerve XII, autonom-
ic neurons of the spinal cord, ganglion cells of the adrenal 
medulla, dorsal root ganglia, paraspinal sympathetic gan-
glia, myenteric ganglia of the stomach and subepicardial 
autonomic ganglion of the heart. Inclusions were not pres-
ent in oligodendrocytes, anterior horn neurons of the spi-
nal cord, neurons of sural and sciatic nerves, and cells of 
skeletal muscles, urinary bladder and esophagus. Purkinje 
cells did not present inclusions either, but exhibited degen-
erative axonal swelling (torpedo formation) and Bergman 
gliosis23-25. The presence of inclusions has not been evalu-
ated in large cohorts of patients. It varies substantially be-
tween the few reported cases, and a possible relationship 
with FXTAS clinical variability has been suggested. How-
ever, further studies are necessary to clarify this issue25.
figure. MRI features of a fragile X-associated 
tremor and ataxia syndorme patient: [A] in-
creased T2 signal intensity (arrows) in white 
matter of the middle cerebellar peduncles; 
[B] increased signal intensity (arrow) on FLAIR 
images in periventricular and deep white 
matter of the hemispheres.
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The neuroanatomical and neuropathological find-
ings could explain the clinical phenotypes of FXTAS pa-
tients: the brain atrophy in frontal and parietal regions 
associated with demyelination of the cerebral white mat-
ter and presence of inclusions in the cerebral neocortex, 
hippocampus and basal ganglia might explain the frontal-
subcortical type of dementia with its cognitive and behav-
ioral disturbances. The motor abnormalities could be the 
consequence of cerebellar degeneration associated with 
the presence of inclusions in substantia nigra, basal gan-
glia and brainstem. Inclusions in spinal cord probably ex-
plain the autonomic dysfunctions10,23,24. Recently, the pres-
ence of inclusions was reported in the pituitary gland and 
Leydig cells; moreover, hypothyroidism has been reported 
to be common in premutated women with FXTAS. These 
observations led to the proposal of hormonal dysfunction 
also being a feature of the clinical picture of FXTAS26,27.
FXTAS may affect premutated women, but the syn-
drome predominantly affects male carriers. This gender-
related difference might be the consequence of the ran-
dom inactivation of one X chromosome in somatic cells of 
females. Premutation carriers, being mosaic of cells with 
the premutation or the normal allele as the active one, 
would have the symptoms alleviated or absent. A hor-
monal factor is also a possibility that cannot be excluded2.
Possible molecular mechanism causing the fxTas 
The two to 10 times higher levels of the FMR1 mRNA, 
associated with a mild decrease of FMRP, represent the 
molecular phenotype in premutated carriers compared to 
normal individuals. This molecular imbalance would be 
the consequence of a feedback mechanism probably relat-
ed to a less effective processing of FMRP synthesis. The ex-
panded (CGG)n in the premutation mRNA would impair 
the protein synthesis, and the consequent reduced levels 
of FMRP would in turn lead to an elevated production of 
the mRNA. FXTAS has never been observed in carriers of 
the full mutation of the FMR1 gene. Since these individu-
als do not produce FMRP, the reduction of this protein per 
se cannot be the cause of FXTAS. A toxic-gain-of-func-
tion model of the FMR1 mRNA was then put forward, 
resembling that proposed for myotonic dystrophy2,28-30.
In this model, an over-interaction of trinucleotide-
binding proteins and translational factors with the FMR1 
mRNA would occur due to the excess of the FMR1 mRNA 
and/or to its expanded (CGG)n. As a consequence, the 
amount of these proteins and factors would be reduced 
in the cell pool, thus impairing several cellular process-
es2. These molecular abnormalities are associated with the 
appearance of eosinophilic nuclear inclusions. It was ob-
served that the FMR1 mRNA was sequestered into these 
inclusions in neurons and astrocytes associated to pro-
teins with critical neuronal functions, as myelin basic pro-
tein, lamin A/C, αβ-crystallin, tropomyosin, hnRNPA2/
B1, Pur-α and CUGBP1 in addition to ubiquitin23,31-35. Mi-
croarray expression analysis of plasmids containing pre-
mutated alleles revealed alterations in genes involved in 
several functions as synapses, chaperones, ubiquitination, 
motor coordination and apoptosis36.
It is not precisely known if the process of inclusion 
formation is ubiquitously occurring in different brain 
regions. It is speculated that neurons presenting high 
amounts of FMR1 mRNA and associated proteins would 
request chaperones and components of the ubiquitin-pro-
teasomal pathway, in an attempt to alleviate this molec-
ular abnormality; in case of failure, the inclusions would 
be formed. Depending where this process occurred, the 
inclusions could have an initial protective effect, avoid-
ing cell death, as in the hippocampus, with the highest 
concentration of inclusions. However, in different types 
of cells, the process of inclusion formation could be fast 
and highly toxic, triggering the apoptosis pathway, and 
causing neurodegeneration, as would be the case of the 
loss of Purkinje cells in the cerebellum32,37-39.
FXTAS represents a new class of inclusion diseas-
es. Immunocytochemical studies showed that antibod-
ies anti-tau and anti-α-synuclein did not react against 
the FXTAS inclusions, evidencing a distinct clinical enti-
ty from diseases caused by the accumulation of tau pro-
tein (Pick disease) or synuclein (Parkinson disease). The 
FXTAS inclusions are also polyglutamine-negative, differ-
ing from those in CAG-expansion disorders. Finally, the 
localization of the inclusions (nucleus of neurons and as-
trocytes) distinguishes FXTAS from pathologies present-
ing similar clinical pictures, as multiple system atrophy 
(MSA), in which the inclusions are in the cytoplasm of 
oligodendrocytes2,24.
animal models for fxTas
The animal models constructed to study FXTAS con-
firmed the involvement of the expanded (CGG)n and/or 
the high levels of FMR1 mRNA in the process of inclu-
sions formation.
The first animal used to study FXTAS was a mouse 
which had a constitutional (CGG)8 replaced by an exog-
enous (CGG)9840. This animal showed mild impairment 
of behavior, cognition and neuromotor aspects, associ-
ated to high levels of Fmr1-mRNA (two to four times). 
The inclusions started to appear at the 30th week of life 
and were restricted to neurons, differently from humans 
whose inclusions are also present in astrocytes. Immu-
nocytochemical findings were similar to those in human 
neurons, and the size of the inclusions was directly relat-
ed to the animal age. The absence of inclusions in astro-
cytes could explain the mild clinical picture in this FX-
TAS mouse model23,41.
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Jin and colleagues42 used Drosophila as a model to 
study FXTAS. A human genomic fragment containing a 
(CGG)90 inserted through an expression vector into Dros-
ophila cells was enough to cause neurodegeneration and 
disturb eye morphology, more pronounced with aging. 
Inclusions were observed in the nucleus as well as in the 
cytoplasm, with more than one inclusion per nucleus, 
contrasting with the single and nucleus-restricted inclu-
sions in humans. These differences could reflect different 
protein-mRNA interactions in Drosophila.
Despite of the presence of inclusions in these ani-
mal models, the clinical symptoms and signs were con-
sidered extremely mild when compared to those in hu-
mans. Therefore, they cannot be considered as ideal mod-
els for the human FXTAS phenotype43.
Diagnostic criteria for fxTas
The diagnostic criteria for FXTAS were proposed by 
Jacquemont and coleagues5, in a study of 26 affected in-
dividuals carrying the FMR1 premutation. Each catego-
ry to discriminate FXTAS patients consists of a combi-
nation of clinical, radiological and pathological signs and 
symptoms (Table 1).
Based on these criteria, individuals are considered 
as being definitively affected by FXTAS if they present 
tremor or ataxia and the MCP sign or, otherwise, any 
major clinical or radiological sign associated to the ob-
servation of intranuclear inclusions in postmortem stud-
ies. Patients with a probable diagnosis of FXTAS present 
tremor and ataxia or the MCP sign associated with par-
kinsonism, memory or executive function deficit. Final-
ly, possible FXTAS is attributed to those patients present-
ing ataxia or tremor, associated with white matter lesions 
or brain atrophy.
Although these signs and symptoms allow the estab-
lishment of FXTAS diagnosis with different degrees of 
certainty, the presence of the FMR1 premutation is man-
datory for the final diagnosis. The detection of the pre-
mutation allows associating specific signs and symptoms 
to FXTAS, which, in a different circumstance, would be 
attributed to idiopathic neurodegenerative disease44. On 
contrary, the absence of the FMR1 premutation in the 
presence of major recognized clinical signs of FXTAS, 
including the presence of the MCP sign in MRI, excludes 
FXTAS diagnosis45.
The establishment of criteria to characterize the dis-
ease has improved the initial diagnosis as FXTAS, which 
is rarely done. The study of 56 FXTAS patients revealed 
that 98 different diagnoses were attributed to the patients 
before the definition of FXTAS20. Moreover, the clinical 
variability of the FXTAS, in terms of severity and disease 
progression, points to the interaction of genetic, neuronal 
and environmental factors, confusing the identification of 
at-risk individuals. For instance, significant motor impair-
ment after surgical procedures involving general anesthe-
sia has been reported in FXTAS patients5,46. This variabil-
ity also brings difficulties to the categorizing of patients 
according to the proposed criteria10,19,39,47,48. Several stud-
ies reported atypical FXTAS patients. There are descrip-
tions of asymptomatic premutation carriers whose image 
exam revealed the presence of white matter abnormalities 
or the MCP sign, thus indicating that MRI can evidence 
alterations before FXTAS clinical manifestations in elder-
ly patients9,22,49,50. In some premutation carriers, the major 
clinical symptom was dementia without a clear evidence 
of motor impairment51,52. In a 65-year-old carrier of a pre-
mutation, a rapid cognitive decline was the major clinical 
symptom, and the postmortem analysis revealed the asso-
ciation of FXTAS and Alzheimer disease. The association 
of these two neurodegenerative diseases was proposed to 
explain the fast progression of the clinical picture46.
Despite the established diagnostic criteria being an in-
valuable tool for FXTAS diagnosis, the atypical cases call 
for a detailed study of neurological impairments in premu-
Table 1. Diagnostic criteria for FXTAS*.
Criteria
Molecular (mandatory) FMR1 premutation: 55<CGG<200
Diagnostic Definite One major clinical + One major radiological or
One major clinical + Intranuclear inclusions (postmortem)
Probable Two major clinical or
One minor clinical + One major radiological
Possible One major clinical + One minor radiological
Clinical Major Intention tremor and cerebellar ataxia
Minor Parkinsonism; moderate to severe working memory deficit; executive function deficit
Radiological Major MRI white matter lesions in the middle cerebellar peduncle (MCP sign)
Minor MRI lesions in the cerebral white matter; moderate to severe generalized brain atrophy
*Based on Jacquemont and coleagues5 and Berry-Kravis and coleagues57. FXTAS: fragile X-associated tremor and ataxia syndrome; MRI: magnetic resonance 
imaging; MCP: middle cerebellar.
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tation carriers to evaluate how frequent these exceptions 
are19,20,53. A point that must be addressed is the possibili-
ty of detecting specific symptoms of FXTAS, as cognitive 
decline and radiological signs, in the initial stages of adult-
hood. This issue is important in two aspects: [1] to predict 
which carriers are in risk to develop FXTAS and [2] to un-
derstand how the high levels of FMR1-mRNA throughout 
lifespan could damage susceptible neural networks54,55.
Premutation screening in patients 
with movement disorders
In an attempt to better understand the clinical man-
ifestations of the FXTAS, FMR1 premutation screenings 
have been performed in cohorts of patients presenting 
movement disorders. Clinical symptoms of FXTAS over-
lap with those of other neurological disorders as cerebel-
lar ataxia, essential tremor, Parkinson disease and multi-
ple system atrophy19,44,56. 
FMR1 premutation screenings performed so far re-
vealed a low frequency in movement disorders cohorts. 
However, in a meta-analysis of cross-sectional studies in 
men with ataxia, the prevalence of the premutation was 
1.5%, thirteen times more than expected considering the 
premutation frequency in the general population, and the 
frequency among patients with the cerebellar subtype of 
multiple system atrophy was 2.4%; for other movement 
disorders, the screening has not been rewarding. In most 
of the premutation carriers detected in these studies, the 
clinical features suggested the FXTAS diagnosis (review 
in Berry -Kravis and coleagues57). 
At the same time, these studies showed that the (CGG)n 
size of the detected premutations were as expanded as 
the (CGG)n in the FXTAS patients from FXS families (i.e., 
~70<CGG<130). It is possible that the premutation fre-
quency in movement disorders cohorts is underestimat-
ed due to several factors: [1] inclusion of patients under 
55 years of age, when FXTAS is not commonly observed; 
[2] small size of cohorts; [3] previously selection of pa-
tients through specific criteria that could have excluded 
FXTAS patients2,50,57-59. Up to now, which movement dis-
orders are more suitable to be screened for the presence 
of the FMR1 premutation remain unknown60,61.
fxTas frequency
The first study on the frequency of FXTAS among pre-
mutated men from FXS families56 revealed an age-depen-
dent frequency: 17% among premutation carriers between 
50 to 59 years of age; 38% among those between 60-69 years; 
47% in the group between 70-79 years, and 75% among 
carriers aged over 80 years. The mean frequency of FXTAS 
estimated among male carriers over 50 years was 39%.
Although some comparative analyses on FXTAS pa-
tients did not reveal an effect of the size of the (CGG)
n on certain aspects of the disease, such as onset of 
signs, life expectancy and severity of neuropsychiatry 
symptoms10,11,12,19,62,63, several recent studies produced 
strong evidence of the effect of the size of the (CGG)n 
on FXTAS manifestations, including cognitive and exec-
utive skills, motor dysfunctions, brain volumetric mea-
sures, initial age of symptoms and number of cells with 
intranuclear inclusions22,23,49,54,64-66. The influence of the 
repeat size on the penetrance of the disease is also sup-
ported by the finding that 86% of individuals with FX-
TAS have (CGG)>7059. Taken together, available data sug-
gest that FXTAS is most often associated with these large 
CGG repeats, although not exclusively4.
Based on the premutation frequency of 1:800 men 
from the general population67 and a penetrance for the 
disease of about 40%, the expected FXTAS frequency in 
men over 50 years of age would be about 1:2,000 in the 
general population6. However, considering that alleles 
with (CGG)<70 are less likely to be associated with FX-
TAS, and that only 22% of the premutations in the gen-
eral population have (CGG)>70, the expected frequency 
of the disease would lower to about 1:10,000 men. In a 
conservative calculation that considers premutations in 
the range 66<CGG<70, this frequency would reach about 
1:5,000 men in the general population. In spite of these 
doubts on its real frequency as well as on the contribution 
to mortality and morbidity of elderly individuals, probably 
FXTAS is the most common cause of tremor and ataxia 
due to a single gene alteration4. It appears at least as prev-
alent as neurodegenerative diseases such as multiple sys-
tem atrophy and amyotrophic lateral sclerosis57.
These estimations point to the underdiagnosing of FX-
TAS. In addition to the restricted knowledge about this 
syndrome, other factors certainly contribute to this situa-
tion. The clinical variability in FXTAS presentation might 
cause, for example the exclusion of those cases where the 
major symptom is dementia without motor impairment. 
Also, the clinical manifestations of FXTAS in elderly pa-
tients might be interpreted as consequence of the natu-
ral process of aging.
Treatment
There is no specific treatment to counteract the ex-
cess of the FMR1 mRNA in the cells of FXTAS patients. 
In theory, drugs aimed at suppressing or diminishing the 
interaction between the mRNA CGG repeat and proteins 
could hinder the sequestration of the latter, maintaining 
normal protein levels. RNA interference might be an in-
teresting approach to be explored43.
Therapeutic attempts towards FXTAS patients are 
based on the treatment of disorders presenting with sim-
ilar symptoms. The medicines are used, basically, to alle-
viate symptoms related to tremor, equilibrium coordina-
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tion, parkinsonism, sleep problems, anxiety, mood alter-
ations, memory problems and pain10,53,68. Some interven-
tions have produced reasonable results27,57 (Table 2).
ConClusions
The identification of the FXTAS, a late onset-neuro-
logical progressive disease without cure, affects genet-
ic counseling in FXS families. Before 2001, genetic tests 
to identify carriers of the premutation in these families 
were performed in adults to assist them about the risks of 
mental retardation in their offspring. Nowadays, the de-
tection of the FMR1 premutation, especially in men, has 
brought ethical issues, mainly the fact that it is predictive 
for an incurable disease, a situation akin of the screening 
of the HTT gene mutation for Huntington disease or the 
ApoE4 variant for Alzheimer disease69.
As far as we know, there are just a few reports con-
cerning aspects of FXTAS in Brazil9,52,70,71. The disease has 
been first recognized by geneticists in the study of frag-
ile X families. The knowledge of this relatively new syn-
drome by physicians and health professionals is funda-
mental for diagnosis and proper assistance to FXTAS pa-
tients to be achieved. The diagnosis of FXTAS in a family 
might also lead to the identification of premutation carri-
er women in risk for FXS in their offspring, or to a here-
tofore unknown diagnosis of FXS in a child. 
The presence of the FMR1 premutation is recom-
mended to be evaluated in men and women with late-on-
set intention tremor, cerebellar ataxia of unknown cause, 
dementia (mainly if associated to movement disorders) or 
MCP sign revealed by MRI. Major concern should be giv-
en to symptomatic individuals with [1] familial history of 
FXS or mental retardation without a diagnosis; [2] female 
relatives presenting premature menopause; [3] relatives 
with ataxia, neurological or psychiatric problems13,20,44,57,72. 
The standards and clinical guidelines for FXTAS and FXS 
can be accessed at the American College of Medical Ge-
netics web site  (http://www.acmg.net/Pages/ACMG_ 
Activities/stds-2002/fx.htm)73.
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